-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 1, the CDE official website showed that Hengrui Medicine's carrelizumab+famitinib+SHR1802 combination therapy was approved for clinical use in advanced solid tumors
SHR1802 is a LAG3 monoclonal antibody
In China, although 10 companies have deployed this target, it is still in the early stage of clinical development
Global R&D layout
Global R&D layoutLAG-3 is mainly expressed on activated T cells and some NK cells, and negatively regulates the cell proliferation, activation and homeostasis of T cells
According to the Insight Global New Drug Database, there are currently as many as 40 antibody drugs targeting LAG-3 under development, including 27 monoclonal antibodies, 12 double antibodies, and 1 fusion protein
Global R&D Status of LAG-3 Target
From: Insight database (http://db.
As of December 1, 2021
Bristol-Myers Squibb's Relatlimab is the first LAG-3 inhibitory monoclonal antibody to enter the clinic
Based on this clinical practice, BMS submitted a BLA application to the FDA in September this year and was granted priority review qualifications
Merck and MacroGenics are the two competitors whose progress is closest to BMS
China's R&D is still in its early stages
China's R&D is still in its early stagesAccording to the Insight database, a total of 13 new drugs targeting LAG-3 are under development in China
Domestic research and development progress of LAG3 target
Finished by Insight, as of December 1, 2021
Take PD-(L)1+LAG-3 combination therapy as an example.
Although Junshi Biopharmaceuticals did not have a self-developed LAG-3 antibody drug that entered the clinic, it has teamed up with Wei Li Zhibo to launch a phase I clinical trial of teriprizumab combined with LAG-3 monoclonal antibody LBL-007 for the first-line treatment of melanoma, and Phase Ib/II clinical trials of a variety of solid tumors
In the development of the LAG3 target, Shimai Pharmaceutical's DNV3 has also adopted a differentiated development strategy for indications.
In the field of double antibodies, in addition to Cinda’s IBI323 and Zai Lab’s MGD-013, it also includes the EMB-02 of Anmai Bio, which is the fastest-growing one among domestic companies’ independent research and development of PD-1/LAG3 double antibodies.
